A Phase 1, Open-label, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational Seasonal Quadrivalent Influenza mRNA Vaccine CVSQIV Administered Intramuscularly in Healthy Younger and Older Adults
Latest Information Update: 08 Jun 2023
At a glance
- Drugs CV 7301 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; First in man
- Sponsors CureVac
Most Recent Events
- 05 Jun 2023 Status changed from active, no longer recruiting to completed.
- 25 May 2022 Status changed from recruiting to active, no longer recruiting, according to a CureVac media release.
- 16 Feb 2022 New trial record